GTS Securities’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-60,200
Closed -$3.97M 2173
2024
Q3
$3.97M Buy
60,200
+22,100
+58% +$1.61M 0.01% 1050
2024
Q2
$3.52M Buy
38,100
+8,000
+27% +$708K 0.01% 1095
2024
Q1
$2.88M Sell
30,100
-20,600
-41% -$1.73M 0.01% 1233
2023
Q4
$3.87M Sell
50,700
-7,900
-13% -$550K 0.01% 1179
2023
Q3
$4.06M Buy
+58,600
New +$4.71M 0.01% 1052

Other funds holding EW

GTS Securities's EW Position: Q1 2026 in Review

GTS Securities reduced its Edwards Lifesciences (EW) stake by 11% in Q1 2026, selling an estimated $50.8K and leaving 4,847 shares worth $388K. The position accounts for 0.01% of the portfolio, ranked #911.

GTS Securities first reported a position in EW in Q3 2023 and has held it in 8 quarters since. The position peaked at $2.17M in Q4 2023. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • GTS Securities held 4,847 shares of Edwards Lifesciences worth $388K as of Q1 2026.
  • GTS Securities sold 616 Edwards Lifesciences shares in Q1 2026, an estimated $50.8K.
  • Edwards Lifesciences made up 0.01% of GTS Securities's portfolio in Q1 2026, its #911 holding.
  • GTS Securities first reported a position in Edwards Lifesciences in Q3 2023 and has held it in 8 quarters since.
  • GTS Securities's Edwards Lifesciences position peaked at $2.17M in Q4 2023.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.